Welcome to LookChem.com Sign In|Join Free
  • or
GSK163090 is a chemical compound that has been extensively studied for its potential therapeutic effects in various medical conditions. It is a potent and selective antagonist of the tachykinin neurokinin 1 (NK1) receptor, which plays a crucial role in the regulation of pain and inflammation. The ability of GSK163090 to effectively block the activation of NK1 receptors results in reduced pain sensitivity and inflammation, making it a promising candidate for the treatment of chronic pain, migraine, and inflammatory diseases. Furthermore, its potential use in managing substance abuse and addiction is being explored, as the NK1 receptor is implicated in the reward and reinforcement pathways in the brain. Further research and clinical trials are necessary to fully comprehend the therapeutic potential of GSK163090 in treating these diverse conditions.

844903-58-8

Post Buying Request

844903-58-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

844903-58-8 Usage

Uses

Used in Pharmaceutical Industry:
GSK163090 is used as a therapeutic agent for the treatment of chronic pain, as it effectively reduces pain sensitivity by blocking the activation of NK1 receptors.
GSK163090 is used as a treatment for migraine, leveraging its ability to block NK1 receptors and alleviate the pain and inflammation associated with this condition.
GSK163090 is used as an anti-inflammatory agent, as its action on NK1 receptors helps in reducing inflammation in various inflammatory diseases.
Used in Substance Abuse Management:
GSK163090 is used as a potential treatment for substance abuse and addiction, due to its influence on the reward and reinforcement pathways in the brain through the NK1 receptor.
Used in Research and Development:
GSK163090 is used as a research tool to further understand the role of NK1 receptors in pain, inflammation, and addiction, contributing to the development of new therapeutic strategies and interventions.

Check Digit Verification of cas no

The CAS Registry Mumber 844903-58-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,4,9,0 and 3 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 844903-58:
(8*8)+(7*4)+(6*4)+(5*9)+(4*0)+(3*3)+(2*5)+(1*8)=188
188 % 10 = 8
So 844903-58-8 is a valid CAS Registry Number.

844903-58-8Relevant academic research and scientific papers

Application of the quality by design principles for the development of the crystallization process for a piperazinyl-quinoline and definition of the control strategy for form 1

Cimarosti, Zadeo,Rossi, Sara,Tramarin, Davide,Laval, Gilles,Stabile, Paolo,Giubellina, Nicola,Maton, William,Allieri, Brigida,Campi, Francesca,Cooke, Jason,Westerduin, Pieter

, p. 1598 - 1606 (2013/02/25)

The studies carried out to develop a robust crystallization method for the substituted piperazinyl-quinoline (1) a compound potentially active in the treatment of depression, are described in this contribution. These studies include the control of a solva

Route selection and process development for a 5-piperazinylquinaldine derivative for the treatment of depression and anxiety

Cimarosti, Zadeo,Giubellina, Nicola,Stabile, Paolo,Laval, Gilles,Tinazzi, Francesco,Maton, William,Pachera, Roberta,Russo, Paola,Moretti, Ramona,Rossi, Sara,Cooke, Jason W. B.,Westerduin, Pieter

, p. 1287 - 1296 (2012/01/06)

1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl) -2-imidazolidinone, 1, was identified as a potential drug for the treatment of depression and anxiety. Herein is described the work carried out to select the manufacturing route and the proces

Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl) -2-imidazolidinone (GSK163090), a potent, selective, and orally active 5-HT 1A/B/D receptor antagonist

Leslie, Colin P.,Biagetti, Matteo,Bison, Silvia,Bromidge, Steven M.,Di Fabio, Romano,Donati, Daniele,Falchi, Alessandro,Garnier, Martine J.,Jaxa-Chamiec, Albert,Manchee, Gary,Merlo, Giancarlo,Pizzi, Domenica A.,Stasi, Luigi P.,Tibasco, Jessica,Vong, Antonio,Ward, Simon E.,Zonzini, Laura

experimental part, p. 8228 - 8240 (2011/02/21)

In an effort to identify selective drug like pan-antagonists of the 5-HT1 autoreceptors, studies were conducted to elaborate a previously reported dual acting 5-HT1 antagonist/SSRI structure. A novel series of compounds was identifie

QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS

-

Page/Page column 64, (2008/06/13)

Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 844903-58-8